Abstract | BACKGROUND: METHODS: Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS: Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n=59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS: A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.
|
Authors | Thomas E Witzig, Arturo Molina, Leo I Gordon, Christos Emmanouilides, Russell J Schilder, Ian W Flinn, Mohamed Darif, Roger Macklis, Katie Vo, Gregory A Wiseman |
Journal | Cancer
(Cancer)
Vol. 109
Issue 9
Pg. 1804-10
(May 01 2007)
ISSN: 0008-543X [Print] United States |
PMID | 17380530
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright (c) 2007 American Cancer Society |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
- Immunoconjugates
- Yttrium Radioisotopes
- Rituximab
- ibritumomab tiuxetan
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
(therapeutic use)
- Drug Resistance, Neoplasm
- Humans
- Immunoconjugates
(therapeutic use)
- Lymphoma, B-Cell
(drug therapy, mortality, radiotherapy)
- Neoplasm Recurrence, Local
(drug therapy, mortality)
- Radioimmunotherapy
(methods)
- Rituximab
- Yttrium Radioisotopes
(therapeutic use)
|